Results 161 to 170 of about 12,392,515 (266)

Concizumab prophylaxis in a 2-year-old patient with severe hemophilia B and inhibitor: a case report. [PDF]

Front Pharmacol
Yuan M, Nusrat S, Khan O.
europepmc   +1 more source

Long Term Follow Up of Hereditary Thrombotic Thrombocytopenic Purpura on Plasma Therapy for 9 Years: A Case Report

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT A 7.6‐year‐old boy with hTTP had fever‐induced hemorrhagic rash, MAHA, cerebral infarction, and renal impairment. After plasma therapy, symptoms were partially relieved; 9‐year follow‐up showed regular plasma transfusion was needed, with CKD Stage 3.
Dai Xiaomei, Chen Ruyue, Wu Shuang, Tang Hanyun, Lin Qiang, Li Xiaozhong   +5 more
wiley   +1 more source

Physiologically Based Pharmacokinetic (PBPK) Modeling of FIX in Pediatric Hemophilia B: Extravascular Distribution and Dosing Optimization. [PDF]

Pharmaceutics
Liu M, Liu G, Ling Q, Chen Y, Xu H, Wu R, Chen Z, Zhao L.   +7 more
europepmc   +1 more source

How to Avoid Misdiagnosing Primary Spinal Epidural Abscess as Spinal Epidural Hematoma: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Spinal epidural abscess (SEA) is an easily misdiagnosed disease. We report a case of primary SEA (PSEA) that was misdiagnosed as spinal epidural hematoma (SEH) and analyze the reasons. The misdiagnosis was confirmed intraoperatively. Comprehensive analysis is crucial for the diagnosis of PSEA and its differential diagnosis from SEH.
Sheng‐Wei Meng, Qian Liu, Yong‐Sheng Zhao   +2 more
wiley   +1 more source

Operationalizing Precision Medicine in Drug Development: Predictive Biomarkers, Companion Diagnostics, and Regulatory Pathways

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 914-929, October 2026.
Precision medicine offers the opportunity to improve the benefit–risk profile of new therapies by prospectively identifying patients most likely to respond or least likely to experience harm; however, its systematic integration into drug development remains inconsistent outside oncology.
Ingrid Holst‐Laubjerg, José M.A. Moreira   +1 more
wiley   +1 more source

Peripheral Seal Composite Barrier (PSCB) for Management of Palatal Donor Sites in Mucogingival Surgery: A Randomized Clinical Trial

Clinical and Experimental Dental Research, Volume 12, Issue 5, October 2026.
ABSTRACT Objectives Management of the palatal donor site following periodontal plastic surgery remains challenging because of postoperative pain, bleeding, and patient discomfort. This study aimed to evaluate the efficacy of a chairside‐fabricated composite barrier in reducing morbidity at the palatal donor site.
Moein Khojaste, Farid Shiezadeh, Zahra Moslehitabar   +2 more
wiley   +1 more source

Development of an Agent-Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec. [PDF]

CPT Pharmacometrics Syst Pharmacol
Li Y, Nandy P, Jordie E, Knab T, Peppel K, Kirouac DC, Wilkins AK, Nuthalapati S.   +7 more
europepmc   +1 more source

Factor VIII inhibitors demonstrate type I or type II kinetics in high‐titre alloantibodies and autoantibodies

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
The inhibitor kinetics type cannot be used by itself to determine auto‐ versus allo‐anti‐FVIII antibody type. To characterise inhibitor kinetics in inherited haemophilia A (HA) and acquired haemophilia A (AHA) patients in our centre, results show that inhibitors for both HA alloantibodies and AHA autoantibodies may exhibit either type I or type II ...
Cuicui Qiao, Jie Wang, Tiantian Wang, Hehe Wang, Yingfang Pan, Wei Liu, Yan Cheng, Feng Xue, Man‐Chiu Poon, Xinsheng Zhang, Yunhai Fang   +10 more
wiley   +1 more source

Safety, efficacy, and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B. [PDF]

Blood Adv
Samelson-Jones BJ, Rasko JEJ, Ducore JM, McGuinn CE, George LA, von Mackensen S, Borgonuovo G, Agathon D, Smith L, Wilcox LJ, Biondo F, Plonski F.   +11 more
europepmc   +1 more source

Teaching Cell and Gene Therapy in Genetic Counseling Programs: Survey Findings and Suggested Practical Resources for Integration

Journal of Genetic Counseling, Volume 35, Issue 5, October 2026.
ABSTRACT As cell and gene therapies (CGTs) advance through clinical trials into clinical practice, it becomes increasingly important for genetic counselors (GCs) to understand these therapeutics to discuss them with patients. Despite the apparent need for GCs to obtain CGT‐related education, little is known about the training GCs receive on CGT topics ...
Mariel Sebby, Lily McConachie, Leah Wetherill, Paula Delk, Emily L. Hopewell   +4 more
wiley   +1 more source